Member Info for Brand

👍👍👍

"Overall, this study provides a BALF single-cell atlas of Omicron critical patients, and suggests that alveolar interferon-responsive neutrophils and macrophages may extricate SARS-CoV-2 Omicron critical patients from the nasty fate of sepsis.

Genuine Question to any who may know - based on the info we've seen so far, the proposed trial looks to be "multi-viral" - assuming this is indeed the case, would this be the first "multi-viral respiratory trial" of its kind?

Something to consider with any auto-abs test. While.auto-abs to INFb are apparently the most rare of any specific IFN, they do exist - so if you were planning to treat someone with INFb, knowing they did or did not have Auto-Abs to INFb would be pretty important.

My Pleasure John.. have only had a chance to skim it so far but certainly must be a positive that the details have finally been published.

It's been one of the mysteries of the Universal Data released so far. So much talk about Auto-Abs at the AGM last year and specifically this test, but not even a hint of Auto-Abs from Universal.

Some may recall the company stating at last years AGM they were working with JL Casanova on the INF Auto-Abs test/assay.

Well, here it is...

https://x.com/EricTopol/status/1838300181475004766?t=yfzDJ9k4f9ePaenWuvEHqQ&s=19

This was in the works before the election and was finally made public by the new govt 2 weeks ago. Seems to clear the tracks for any public/private partnership type trials, sng001 or otherwise. Haven't been any trials announced in relation since.

https://www.gov.uk/government/news/uk-secures-400-million-investment-to-boost-clinical-trials

Up to £400 million of investment will support faster patient access to cutting-edge treatments, strengthen clinical trials and improve medicines manufacturing in the UK

18 new clinical trials hubs will be created across UK to accelerate research

https://www.gov.uk/government/news/uk-secures-400-million-investment-to-boost-clinical-trials

It's not called "synairgen" because it's only meant to be used on its own, is it?

Strange that Paraxel would be recruiting for this COPD trial rn, considering there are already drugs approved and that means no others will be

https://pxlcrs.my.site.com/portal/s/trial-details?clinicalStudyId=a273V000000yHi2QAE&recordTypeId=a2N3V0000016vJOUAY&type=signup&language=en_US&loc=LON&rpcid=a2BP7000000CRcLMAW

Absolutely Tommy. I don't believe anything has been published beyond the press release at this point.

Cheers PMJH,

I agree - focus had to be on what the company says/does next. It's peculiar tho that this trial, of which the agents were due to be announced in "early 2024" had the announcement delayed until the very end of H1, and that they announced only two of the stated three treatments

The only way Purdah would come in to play with BARDA, is if there were some sort of joint US/UK involvement in SNG being on the trial.

Https://medicalcountermeasures.gov/newsroom/2024/ards/#:~:text=BARDA%20has%20selected%20host%2Ddirected,Administration%20(FDA)%20for%20ARDS.

This PT was announced by BARDA last week. It's almost certainly what the company were aiming at with the Rick Bright link up. The interesting part is the trial was announced with just 2 of the 3 planned agents....

"An additional company and product may be added to the clinical trial at a later time.

Advanced development of host-directed therapeutics is a critical element of pandemic influenza preparedness and response, as outlined in BARDA’s 2022-2026 Strategic Plan. By supporting the development of agile medical countermeasures that can pivot and address multiple public health threats, BARDA enables national preparedness for diseases caused by known and unknown threats."

Election was called out of the blue on 22 May, with the gov having advised there would be no election until the autumn...

Https://www.nihr.ac.uk/researchers/i-need-help-to-deliver-my-research/outputs-and-branding.htm

"If you are planning communications to announce that you have received NIHR funding for a new research project, this is prohibited until after the election. Please contact your NIHR grant manager if you have further questions."

Well this is incrediblely interesting. Excellent find thanks for sharing

To borrow a comment from another well informed poster. I believe the company were quite busy 2020-2022.

This data, when added to the various data re COVID, RVIs, Universal etc does make an incredibly compelling case for SNG001

Conclusions

This exploratory study provides evidence that the recombinant interferon-β1a SNG001 is well tolerated in patients with COPD, and upregulates the lung’s antiviral defences to accelerate viral clearance. In particular in patients with a moderate COPD exacerbation, there was evidence that SNG001 provided an improvement in PEF and potentially prevented secondary bacterial infection. These findings warrant investigation in a larger study – especially one that includes an evaluation of bacterial load, either by culture or molecular methods.

https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-024-02854-7

Of note, in the majority of randomized controlled trials evaluating IFN-I as a candidate COVID-19 therapeutic, IFN-I has been administered as a subcutaneous injection. Three clinical trials to date, however, have tested inhaled nebulized IFNβ-1a. Two of these trials were conducted in patients hospitalized with COVID-19 and showed that treatment with inhaled nebulized IFNβ-1a (SNG001) resulted in greater odds of improvement, faster recovery, and reduced progression to severe disease or death, respectively (126, 127). The third trial was conducted in COVID-19 outpatients, and no differences in time to symptom improvement or viral clearance were noted between SNG001 and placebo groups. However, a trend in lower hospitalizations was observed in patients treated with SNG001 [86% relative risk reduction (P = 0.07)] (128). These three studies highlight the need for additional research into the effect of the route of administration/site of drug delivery not just for IFN-I but for all COVID-19 candidate therapeutics. In particular, given that SARS-CoV-2 is a respiratory virus, efforts should focus on evaluating nasal and oral inhalation routes to promote drug distribution to the respiratory mucosa.

https://journals.asm.org/doi/10.1128/jvi.01204-23

Surprised this hasn't been posted yet...

UNIVERSAL data poster session at ATS

"This abstract is funded by: Janssen, AstraZeneca"

https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A6245